Approval · Notice of Compliance 1597 · 1999
LIPITOR: Notice of Compliance 1597
Issued January 12, 1999
A Notice of Compliance is Health Canada’s approval of a drug submission: a new drug, a new use or form, or a change to an approved one. The product itself is in the Drug Product Database, with its current status.
- Notice number
- 1597
- Date
- January 12, 1999
- Company
- Parke-Davis Division, Warner-Lambert Canada Inc.Scarborough, Ontario, Canada
- Product type
- Prescription Pharmaceutical
- Submission
- Supplement to a New Drug Submission (SNDS), supplement
- Submission class
- Other
- Reason
- New indications: as an adjunct to diet for the reduction of elevated total cholesterol in dysbetalipoproteinemia (type iii), hypertriglyceridemia (type iv), and homozygous familial hypercholesterolemia
- Therapeutic class
- Lipid metabolism regulator
Products in this notice
| Brand | DIN | Status today |
|---|---|---|
| LIPITOR | Not yet assigned | — |
Medicinal ingredients
- ATORVASTATIN CALCIUM 10 MG per TAB
- ATORVASTATIN CALCIUM 20 MG per TAB
- ATORVASTATIN CALCIUM 40 MG per TAB